Announcements
- Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
- Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Key statistics
On Friday, Cingulate Inc (CING:NAQ) closed at 0.7228, 11.20% above the 52 week low of 0.65 set on May 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.7184 |
---|---|
High | 0.73 |
Low | 0.68 |
Bid | 0.6803 |
Offer | 0.72 |
Previous close | 0.718 |
Average volume | 134.32k |
---|---|
Shares outstanding | 6.23m |
Free float | 4.96m |
P/E (TTM) | -- |
Market cap | 4.37m USD |
EPS (TTM) | -22.66 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 20:59 BST.
More ▼